Immunic (NASDAQ:IMUX) Downgraded by D. Boral Capital to “Hold”

D. Boral Capital lowered shares of Immunic (NASDAQ:IMUX) from a buy rating to a hold rating in a research report sent to investors on Wednesday morning, MarketBeat reports.

Several other analysts have also issued reports on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Immunic in a report on Monday, December 29th. HC Wainwright cut their price objective on Immunic from $8.00 to $5.00 and set a “buy” rating for the company in a report on Monday, March 2nd. raised shares of Immunic to a “strong-buy” rating in a research report on Tuesday, February 3rd. Guggenheim began coverage on shares of Immunic in a research report on Tuesday, March 24th. They set a “buy” rating and a $7.00 target price on the stock. Finally, Wall Street Zen raised shares of Immunic from a “sell” rating to a “hold” rating in a research report on Saturday, April 11th. Two investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $6.17.

Immunic Stock Down 5.9%

IMUX opened at $1.11 on Wednesday. The stock has a fifty day moving average of $1.07 and a 200-day moving average of $0.84. The firm has a market capitalization of $144.81 million, a P/E ratio of -1.59 and a beta of 1.37. Immunic has a 12-month low of $0.51 and a 12-month high of $1.51.

Immunic’s stock is going to reverse split on Monday, April 27th. The 1-10 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Sunday, April 26th.

Immunic (NASDAQ:IMUX) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.02). On average, analysts expect that Immunic will post -0.94 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Immunic

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Qube Research & Technologies Ltd acquired a new stake in Immunic during the third quarter worth about $29,000. Two Sigma Investments LP acquired a new stake in Immunic during the third quarter worth about $52,000. HB Wealth Management LLC acquired a new stake in Immunic during the third quarter worth about $81,000. Seven Fleet Capital Management LP acquired a new stake in Immunic during the fourth quarter worth about $83,000. Finally, Virtu Financial LLC acquired a new stake in Immunic during the third quarter worth about $99,000. 51.82% of the stock is owned by institutional investors and hedge funds.

About Immunic

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.